CUMBERLAND PHARMACEUTICALS (CPIX) Stock Price & Overview

NASDAQ:CPIX • US2307701092

Current stock price

3.05 USD
0 (0%)
Last:

The current stock price of CPIX is 3.05 USD. Today CPIX is down by 0%. In the past month the price decreased by -2.56%. In the past year, price decreased by -38.63%.

CPIX Key Statistics

52-Week Range1.85 - 6.265
Current CPIX stock price positioned within its 52-week range.
1-Month Range2.98 - 3.935
Current CPIX stock price positioned within its 1-month range.
Market Cap
45.628M
P/E
27.73
Fwd P/E
N/A
EPS (TTM)
0.11
Dividend Yield
N/A

CPIX Stock Performance

Today
0%
1 Week
-4.69%
1 Month
-2.56%
3 Months
-22.39%
Longer-term
6 Months -12.61%
1 Year -38.63%
2 Years +90.63%
3 Years +78.36%
5 Years +14.23%
10 Years -35.65%

CPIX Stock Chart

CUMBERLAND PHARMACEUTICALS / CPIX Daily stock chart

CPIX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CPIX. When comparing the yearly performance of all stocks, CPIX is a bad performer in the overall market: 90.64% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CPIX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CPIX. The financial health of CPIX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CPIX Earnings

On March 3, 2026 CPIX reported an EPS of -0.01 and a revenue of 13.68M.

Next Earnings DateMay 12, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.01
Revenue Reported13.68M
EPS Surprise %
Revenue Surprise %

CPIX Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

CPIX Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

CPIX Financial Highlights

Over the last trailing twelve months CPIX reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS increased by 237.5% compared to the year before.


Income Statements
Revenue(TTM)44.52M
Net Income(TTM)-2.84M
Industry RankSector Rank
PM (TTM) N/A
ROA -3.69%
ROE -11.4%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%31.03%
EPS 1Y (TTM)237.5%
Revenue 1Y (TTM)17.57%

CPIX Ownership

Ownership
Inst Owners17.55%
Shares14.96M
Float8.38M
Ins Owners3.59%
Short Float %1.31%
Short Ratio0.89

About CPIX

Company Profile

CPIX logo image Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 93 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Company Info

IPO: 2009-08-11

CUMBERLAND PHARMACEUTICALS

1600 West End Avenue, Suite 1300

Nashville TENNESSEE 37203 US

CEO: A. J. Kazimi

Employees: 93

CPIX Company Website

CPIX Investor Relations

Phone: 18774842700

CUMBERLAND PHARMACEUTICALS / CPIX FAQ

Can you describe the business of CUMBERLAND PHARMACEUTICALS?

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 93 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.


Can you provide the latest stock price for CUMBERLAND PHARMACEUTICALS?

The current stock price of CPIX is 3.05 USD.


What is the dividend status of CUMBERLAND PHARMACEUTICALS?

CPIX does not pay a dividend.


What is the ChartMill technical and fundamental rating of CPIX stock?

CPIX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the GICS sector and industry of CPIX stock?

CUMBERLAND PHARMACEUTICALS (CPIX) operates in the Health Care sector and the Pharmaceuticals industry.


Would investing in CUMBERLAND PHARMACEUTICALS be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CPIX.


Can you provide the ownership details for CPIX stock?

You can find the ownership structure of CUMBERLAND PHARMACEUTICALS (CPIX) on the Ownership tab.